Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment
Author:
Affiliation:
1. Department of Medicine; the University of Hong Kong; Queen Mary Hospital; Hong Kong
2. State Key Laboratory for Liver Research; the University of Hong Kong; Queen Mary Hospital; Hong Kong
Funder
Bristol-Myers Squibb
Publisher
Wiley
Subject
Gastroenterology,Hepatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jgh.12476/fullpdf
Reference31 articles.
1. Lamivudine for patients with chronic hepatitis B and advanced liver disease;Liaw;N. Engl. J. Med.,2004
2. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease;Yuen;Antivir. Ther.,2007
3. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B;Lai;N. Engl. J. Med.,2006
4. Three years of continuous entecavir therapy in treatment-naive chronic hepatitis B patients: viral suppression, viral resistance, and clinical safety;Yuen;Am. J. Gastroenterol.,2011
5. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B;Chang;Hepatology,2010
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Gene-Editing and RNA Interference in Treating Hepatitis B: A Review;Viruses;2023-12-08
2. The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial;Trials;2023-12-02
3. Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection;Biomedicines;2023-07-08
4. Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis;JHEP Reports;2023-06
5. Effectiveness and safety of tenofovir amibufenamide and its comparison with tenofovir alafenamide in patients with chronic hepatitis B: results from a retrospective real-world study;Frontiers in Pharmacology;2023-06-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3